OpenLB
Open Library of Bioscience
Advanced Search
PloS one
2012;7 (3): e33174.

Identification of common biological pathways and drug targets across multiple respiratory viruses based on human host gene expression analysis.

Steven B Smith, William Dampier, Aydin Tozeren, James R Brown, Michal Magid-Slav
Author Information
  1. Steven B Smith: Department of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
PMID: 22432004 DOI: 10.1371/journal.pone.0033174

Abstract

BACKGROUND: Pandemic and seasonal respiratory viruses are a major global health concern. Given the genetic diversity of respiratory viruses and the emergence of drug resistant strains, the targeted disruption of human host-virus interactions is a potential therapeutic strategy for treating multi-viral infections. The availability of large-scale genomic datasets focused on host-pathogen interactions can be used to discover novel drug targets as well as potential opportunities for drug repositioning.
METHODS/RESULTS: In this study, we performed a large-scale analysis of microarray datasets involving host response to infections by influenza A virus, respiratory syncytial virus, rhinovirus, SARS-coronavirus, metapneumonia virus, coxsackievirus and cytomegalovirus. Common genes and pathways were found through a rigorous, iterative analysis pipeline where relevant host mRNA expression datasets were identified, analyzed for quality and gene differential expression, then mapped to pathways for enrichment analysis. Possible repurposed drugs targets were found through database and literature searches. A total of 67 common biological pathways were identified among the seven different respiratory viruses analyzed, representing fifteen laboratories, nine different cell types, and seven different array platforms. A large overlap in the general immune response was observed among the top twenty of these 67 pathways, adding validation to our analysis strategy. Of the top five pathways, we found 53 differentially expressed genes affected by at least five of the seven viruses. We suggest five new therapeutic indications for existing small molecules or biological agents targeting proteins encoded by the genes F3, IL1B, TNF, CASP1 and MMP9. Pathway enrichment analysis also identified a potential novel host response, the Parkin-Ubiquitin Proteasomal System (Parkin-UPS) pathway, which is known to be involved in the progression of neurodegenerative Parkinson's disease.
CONCLUSIONS: Our study suggests that multiple and diverse respiratory viruses invoke several common host response pathways. Further analysis of these pathways suggests potential opportunities for therapeutic intervention.

References

  1. Sci Signal. 2008 Jul 22;1(29):re8 [PMID: 18648074]
  2. PLoS One. 2010 Jan 15;5(1):e8729 [PMID: 20090954]
  3. Methods Mol Biol. 2009;563:177-96 [PMID: 19597786]
  4. Methods Mol Biol. 2007;356:319-50 [PMID: 16988414]
  5. J Pharmacol Exp Ther. 2000 Aug;294(2):701-6 [PMID: 10900250]
  6. PLoS One. 2010 Jun 23;5(6):e11275 [PMID: 20585657]
  7. Bioinformatics. 2001 Jun;17(6):520-5 [PMID: 11395428]
  8. Nat Biotechnol. 2007 Dec;25(12):1383-9 [PMID: 18066032]
  9. Nat Rev Immunol. 2011 Dec 09;12(1):35-48 [PMID: 22158412]
  10. J Cell Physiol. 2011 Dec;226(12):3316-29 [PMID: 21321939]
  11. J Immunol. 2010 Mar 15;184(6):3213-22 [PMID: 20173022]
  12. Mucosal Immunol. 2010 Jan;3(1):69-80 [PMID: 19710636]
  13. Clin Dev Immunol. 2011;2011:103917 [PMID: 21234380]
  14. Pediatrics. 2009 Dec;124(6):1676-9 [PMID: 19948632]
  15. J Neurol. 2003 Oct;250 Suppl 3:III25-9 [PMID: 14579121]
  16. Genomic Med. 2008 Dec;2(3-4):113-25 [PMID: 19459069]
  17. Circ Shock. 1992 Mar;36(3):200-7 [PMID: 1611705]
  18. Clin Microbiol Rev. 2008 Apr;21(2):274-90, table of contents [PMID: 18400797]
  19. FEBS Lett. 2011 Jan 3;585(1):128-32 [PMID: 21094644]
  20. Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13354-9 [PMID: 11078524]
  21. J Virol. 2010 Dec;84(24):12895-902 [PMID: 20926560]
  22. Biochim Biophys Acta. 2009 Jul;1792(7):714-21 [PMID: 18760350]
  23. PLoS One. 2011;6(5):e20495 [PMID: 21655265]
  24. J Pharmacol Exp Ther. 1995 Mar;272(3):1313-20 [PMID: 7891349]
  25. J Immunol. 2007 Mar 1;178(5):3134-42 [PMID: 17312161]
  26. J Infect Dis. 2011 Mar 1;203(5):674-82 [PMID: 21208913]
  27. Neuron. 2003 Mar 6;37(5):735-49 [PMID: 12628165]
  28. Clin Exp Immunol. 2006 Jun;144(3):425-31 [PMID: 16734611]
  29. J Virol. 2001 Dec;75(24):12319-30 [PMID: 11711622]
  30. Nat Rev Immunol. 2012 Jan 06;12(2):125-35 [PMID: 22222875]
  31. Curr Med Chem. 2007;14(18):1966-77 [PMID: 17691939]
  32. J Neurochem. 2005 Apr;93(2):422-31 [PMID: 15816865]
  33. Biochem Biophys Res Commun. 2002 Oct 25;298(2):251-6 [PMID: 12387824]
  34. Future Virol. 2011 Aug;6(8):951-962 [PMID: 21909336]
  35. Int J Cancer. 2011 Jun 15;128(12):2881-91 [PMID: 21165954]
  36. Annu Rev Immunol. 1994;12:881-922 [PMID: 7516669]
  37. J Interferon Cytokine Res. 2011 Jan;31(1):5-11 [PMID: 21226606]
  38. Clin Exp Allergy. 2003 Jun;33(6):795-801 [PMID: 12801315]
  39. J Allergy Clin Immunol. 1997 Jan;99(1 Pt 1):28-37 [PMID: 9003208]
  40. Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):6739-44 [PMID: 21502533]
  41. Immunopharmacology. 1996 Mar;31(2-3):223-35 [PMID: 8861748]
  42. J Comput Aided Mol Des. 2009 Apr;23(4):195-8 [PMID: 19194660]
  43. Virology. 2008 Apr 25;374(1):114-27 [PMID: 18234263]
  44. Science. 2001 Jul 13;293(5528):263-9 [PMID: 11431533]
  45. Neurobiol Dis. 2003 Dec;14(3):357-64 [PMID: 14678753]
  46. Intern Med. 2011;50(15):1605-9 [PMID: 21804290]
  47. J Exp Med. 1997 Feb 3;185(3):461-9 [PMID: 9053446]
  48. J Biol Chem. 2003 Jun 27;278(26):23376-80 [PMID: 12692130]
  49. Inflamm Allergy Drug Targets. 2011 Jun;10(3):171-9 [PMID: 21428909]
  50. PLoS Pathog. 2010 Sep 09;6(9):e1001099 [PMID: 20844577]
  51. Expert Opin Biol Ther. 2009 Sep;9(9):1177-88 [PMID: 19604125]
  52. Clin Infect Dis. 2011 Jan 1;52 Suppl 1:S75-82 [PMID: 21342903]
  53. Nature. 2004 Feb 12;427(6975):636-40 [PMID: 14737177]
  54. Eur J Pharmacol. 1997 Nov 27;339(2-3):215-21 [PMID: 9473138]
  55. Pharmacol Rep. 2010 Nov-Dec;62(6):1148-58 [PMID: 21273672]
  56. J Virol. 2009 Apr;83(7):3039-48 [PMID: 19004938]
  57. J Virol. 2010 Apr;84(7):3528-41 [PMID: 20071566]
  58. Infect Immun. 2011 Apr;79(4):1407-17 [PMID: 21245275]
  59. J Postgrad Med. 2011 Apr-Jun;57(2):153-60 [PMID: 21654146]
  60. J Interferon Cytokine Res. 2011 Jan;31(1):119-30 [PMID: 21190487]
  61. BMC Infect Dis. 2011 Jun 22;11:178 [PMID: 21696601]
  62. Nucleic Acids Res. 2006 Jan 1;34(Database issue):D668-72 [PMID: 16381955]
  63. J Virol. 2011 Jun;85(12):5718-32 [PMID: 21471247]
  64. Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):14063-8 [PMID: 19667183]
  65. J Virol. 2011 Feb;85(3):1360-9 [PMID: 21084488]
  66. Drug Discov Today. 2011 Mar;16(5-6):229-36 [PMID: 21277381]
  67. Oncologist. 2001;6(1):34-55 [PMID: 11161227]
  68. Genomics. 2003 Feb;81(2):98-104 [PMID: 12620386]
  69. Nat Med. 2001 Oct;7(10):1144-50 [PMID: 11590439]
  70. J Clin Invest. 1995 Jul;96(1):549-57 [PMID: 7615827]
  71. Vet J. 2011 Jan;187(1):48-53 [PMID: 20097110]
  72. J Cell Biochem. 2011 Feb;112(2):559-70 [PMID: 21268077]
  73. Am J Respir Crit Care Med. 2008 Nov 1;178(9):962-8 [PMID: 18658112]
  74. Pediatr Neurol. 2011 Jan;44(1):47-51 [PMID: 21147387]
  75. Chin Med J (Engl). 2007 Jan 5;120(1):5-11 [PMID: 17254480]
  76. PLoS One. 2011 Apr 18;6(4):e18928 [PMID: 21533115]
  77. EMBO J. 2011 Jun 21;30(14):2853-67 [PMID: 21694720]
  78. J Thromb Haemost. 2011 Jul;9 Suppl 1:182-8 [PMID: 21781254]
  79. PLoS One. 2009 Dec 14;4(12):e8072 [PMID: 20011590]
  80. Respir Res. 2010 Oct 28;11:147 [PMID: 21029402]
  81. PLoS Pathog. 2011 Apr;7(4):e1002016 [PMID: 21533215]
  82. Am J Respir Cell Mol Biol. 2010 Apr;42(4):404-14 [PMID: 19502390]
  83. Braz J Med Biol Res. 2011 Nov;44(11):1134-40 [PMID: 22011961]
  84. PLoS Med. 2007 May;4(5):e176 [PMID: 17488182]
  85. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6 [PMID: 18048412]
  86. Genomics. 2010 Mar;95(3):138-42 [PMID: 20079422]
  87. Immunology. 1992 Jan;75(1):189-95 [PMID: 1537596]
  88. Am J Respir Cell Mol Biol. 2011 Jun;44(6):906-13 [PMID: 20705938]
  89. Int J Cardiol. 1997 Dec 1;62 Suppl 1:S3-12 [PMID: 9464576]
  90. J Clin Invest. 1996 Feb 15;97(4):915-24 [PMID: 8613544]
  91. BMC Bioinformatics. 2010 Sep 27;11:483 [PMID: 20875095]
  92. Clin Exp Allergy. 2007 Apr;37(4):608-14 [PMID: 17430359]
  93. Clin Exp Immunol. 2011 Oct;166(1):1-15 [PMID: 21762124]
  94. Viral Immunol. 2009 Dec;22(6):343-51 [PMID: 19951172]
  95. Annu Rev Microbiol. 2008;62:171-92 [PMID: 18729734]
  96. PLoS One. 2009 Sep 25;4(9):e7162 [PMID: 19779614]
  97. Clin Immunol. 2003 Jun;107(3):178-85 [PMID: 12804531]
  98. J Neurosci. 2003 Apr 15;23(8):3316-24 [PMID: 12716939]
  99. Hum Mol Genet. 2003 Nov 15;12(22):2957-65 [PMID: 14519684]
  100. Nat Rev Microbiol. 2011 Dec 19;10(2):137-49 [PMID: 22183253]
  101. Cell Host Microbe. 2009 Sep 17;6(3):207-17 [PMID: 19664979]
  102. Curr Opin Immunol. 2010 Feb;22(1):55-62 [PMID: 20137905]
  103. Travel Med Infect Dis. 2008 May;6(3):114-24 [PMID: 18486065]
  104. Retrovirology. 2005 Apr 06;2:24 [PMID: 15813969]
  105. BMC Immunol. 2005 Jan 18;6:2 [PMID: 15655079]

MeSH Term

Antiviral Agents
Databases, Genetic
Gene Expression Profiling
Gene Expression Regulation, Viral
Host-Pathogen Interactions
Humans
Molecular Targeted Therapy
Oligonucleotide Array Sequence Analysis
Proteasome Endopeptidase Complex
Quality Control
RNA, Messenger
Respiratory Syncytial Virus Infections
Respiratory Syncytial Viruses
Signal Transduction
Ubiquitin
Ubiquitin-Protein Ligases

Chemicals

Antiviral Agents
RNA, Messenger
Ubiquitin
Ubiquitin-Protein Ligases
parkin protein
Proteasome Endopeptidase Complex
Journal Article
Article has an altmetric score of 17

Word Cloud

Created with Highcharts 10.0.0pathwaysanalysisrespiratoryviruseshostdrugpotentialresponsetherapeuticdatasetstargetsvirusgenesfoundexpressionidentifiedcommonbiologicalsevendifferentfivehumaninteractionsstrategyinfectionslarge-scalenovelopportunitiesstudyanalyzedgeneenrichment67amongtopsuggestsmultipleBACKGROUND:PandemicseasonalmajorglobalhealthconcernGivengeneticdiversityemergenceresistantstrainstargeteddisruptionhost-virustreatingmulti-viralavailabilitygenomicfocusedhost-pathogencanuseddiscoverwellrepositioningMETHODS/RESULTS:performedmicroarrayinvolvinginfluenzasyncytialrhinovirusSARS-coronavirusmetapneumoniacoxsackieviruscytomegalovirusCommonrigorousiterativepipelinerelevantmRNAqualitydifferentialmappedPossiblerepurposeddrugsdatabaseliteraturesearchestotalrepresentingfifteenlaboratoriesninecelltypesarrayplatformslargeoverlapgeneralimmuneobservedtwentyaddingvalidation53differentiallyexpressedaffectedleastsuggestnewindicationsexistingsmallmoleculesagentstargetingproteinsencodedF3IL1BTNFCASP1MMP9PathwayalsoParkin-UbiquitinProteasomalSystemParkin-UPSpathwayknowninvolvedprogressionneurodegenerativeParkinson'sdiseaseCONCLUSIONS:diverseinvokeseveralinterventionIdentificationacrossbased

Similar Articles

Cited By (46)